Elson M L
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
J Am Acad Dermatol. 1988 Apr;18(4 Pt 1):707-13. doi: 10.1016/s0190-9622(88)70094-8.
The advent of injectable collagen for soft tissue augmentation has opened an entirely new area for the dermatologic cosmetic surgeon and for dermatologists who have a particular interest in the cosmetic aspect of our specialty. Patient demand for correction of soft tissue contour irregularities is high and continues to increase daily. The use of injectable collagen with appropriate technique can provide these patients with significant improvement without great cost or significant side effects. In the year following the introduction of glutaraldehyde cross-linked Zyplast Implant, 188 patients were evaluated for soft tissue augmentation with bovine collagen in my clinical practice. Diagnoses varied from facial elastosis to scars due to acne, pox, trauma, and cancer. Some patients desired changes in facial contour (thicker lips; postrhinoplasty defect). Patient satisfaction was high (83% good or excellent results) and side effects were minimal. In our study we found that 3% of patients demonstrated hypersensitivity to the test implant. Treatment with non-cross-linked Zyderm and Zyplast collagens in the patients with a negative skin test resulted in six hypersensitivity reactions (3%). In these patients reactions were not observed at sites treated only with cross-linked collagen and clinical responses appeared to be directed at the non-cross-linked collagen implant sites. With proper treatment technique and patient consultation, the results obtained with injectable collagen fulfill expectations of treated patients.
可注射胶原蛋白用于软组织填充的出现,为皮肤科美容外科医生以及对本专业美容方面有特殊兴趣的皮肤科医生开辟了一个全新的领域。患者对矫正软组织轮廓不规则的需求很高,且每天都在持续增加。采用适当技术使用可注射胶原蛋白可为这些患者带来显著改善,而无需高昂费用或产生重大副作用。在引入戊二醛交联的Zyplast植入物后的一年里,我在临床实践中对188例患者进行了牛胶原蛋白软组织填充评估。诊断范围从面部弹性组织变性到痤疮、痘疮、外伤和癌症所致的瘢痕。一些患者希望改变面部轮廓(嘴唇增厚;鼻整形术后缺损)。患者满意度较高(83%为良好或极佳效果),副作用极小。在我们的研究中,我们发现3%的患者对试验植入物表现出超敏反应。皮肤试验阴性的患者使用非交联的Zyderm和Zyplast胶原蛋白治疗后出现了6例超敏反应(3%)。在这些患者中,仅用交联胶原蛋白治疗的部位未观察到反应,临床反应似乎针对的是非交联胶原蛋白植入部位。通过适当的治疗技术和患者咨询,可注射胶原蛋白所取得的结果符合接受治疗患者的期望。